Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]
News [6141]
Articles [120]
Editorials [18]
Conferences [181]
elearning [32]
Scientists uncover clues behind drug resistance in bowel cancer
Scientists uncover clues behind drug resistance in bowel cancer
Fixed-duration acalabrutinib-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting
Fixed-duration acalabrutinib-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the...
Thousands of blood cancer patients could benefit from new drug combination
Thousands of blood cancer patients could benefit from new drug combination
Removing a cancer-activated cell type has been shown to virtually eliminate liver metastasis
Removing a cancer-activated cell type has been shown to virtually eliminate liver metastasis
FDA approves darolutamide for metastatic castration-sensitive prostate cancer
FDA approves darolutamide for metastatic castration-sensitive prostate cancer
ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers
ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast...
ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free
ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free
ASCO 2025: First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients with BRAF-mutated metastatic colorectal cancer
ASCO 2025: First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients...
ASCO 2025: Study highlights potential new treatment for aggressive form of acute myeloid leukaemia
ASCO 2025: Study highlights potential new treatment for aggressive form of acute myeloid leukaemia
ASCO 2025: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumours
ASCO 2025: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumours

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation